Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.

Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.

Item
http://www.wikidata.org/entity/Q38566022
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesTreatment optimization for HIV/HCV co-infected patients.Conceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua.Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureVedroprevir in the management of hepatitis C virus infection.Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations.Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States
P2860

Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.

Item
http://www.wikidata.org/entity/Q38566022
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
@en
type
label
Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
@en
prefLabel
Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698